Table 1 Approved drugs with targets in the kallikrein-kinin system
From: Recent advances in the discovery and development of drugs targeting the kallikrein-kinin system
Drug | Class | Approved indication | Ref |
|---|---|---|---|
C1 esterase inhibitor | |||
 Human C1 esterase inhibitor | Protein replacement therapy | Hereditary angioedema (on-demand and prophylaxis) | |
 Conestat alfa | Protein replacement therapy | Hereditary angioedema (on-demand) | [117] |
Coagulation factor XII | |||
 Garadacimab/CSL312 | Monoclonal antibody (fully human) | Hereditary angioedema (prophylaxis) | [27] |
Plasma (P) and tissue (T) kallikrein | |||
 Berotralstat (P) | Small molecule inhibitor | Hereditary angioedema (prophylaxis) | |
 Ecallantide (P) | Inhibitor, protein | Hereditary angioedema (on-demand) | |
 Lanadelumab (P) | Monoclonal antibody (fully human) | Hereditary angioedema (prophylaxis) | |
 Aprotinin (P, T) | Inhibitor, protein | Reduction of perioperative blood loss | |
 Ulinastatin (P, T) | Inhibitor, protein | Sepsis, pancreatitis | |
 Human urinary kallidinogenase (T) | Enzyme replacement therapy | Acute ischemic stroke | [101] |
Bradykinin B2 receptor | |||
 Icatibant | Peptide antagonist | Hereditary angioedema (on-demand) | |